<DOC>
	<DOCNO>NCT02118961</DOCNO>
	<brief_summary>This study design assess immunogenicity safety DTaP vaccine ( BK1301 ) booster dose adolescent . The purpose study follow : - To confirm non-inferiority BK1301 Adsorbed Diphtheria-Tetanus Combined Toxoid ( DT toxoid ) respect booster responses anti-diphtheria toxoid ( anti-D ) anti-tetanus toxoid ( anti-T ) antibodies - To confirm booster response anti-pertussis toxoid ( anti-PT ) anti-Filamentous Hemagglutinin ( anti-FHA ) antibodies 80 % participant receive BK1301</brief_summary>
	<brief_title>Study BK1301 ( DTaP Vaccine ) Booster Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Tetany</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age 11 12 year day injection Received 3 4 dos DTaP vaccine History pertussis , diphtheria , tetanus History anaphylaxis vaccine component Serious condition disease heart , vein , blood , respiratory , hepar , kidney , digestive system , psychiatric nervous system Transfused receive gamma globulin within 3 month , receive highdose gamma globulin within 6 month day injection</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Pertussis</keyword>
	<keyword>DTaP vaccine</keyword>
	<keyword>Adolescents</keyword>
</DOC>